Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study
- PMID: 23861328
- PMCID: PMC3791393
- DOI: 10.1093/eurheartj/eht219
Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study
Abstract
Aims: Antihypertensive drug therapy is a major strategy of stroke prevention among hypertensive patients. The aim of this study was to estimate the excess risk of stroke associated with non-adherence to antihypertensive drug therapy among hypertensive patients.
Methods and results: We conducted a population-based study using records from Finnish national registers for 1 January 1995 to 31 December 2007. Of the 73 527 hypertensive patients aged 30 years or older and without pre-existing stroke or cardiovascular disease, 2144 died from stroke and 24 560 were hospitalized due to stroke during the follow-up. At the 2- and 10-year follow-up after the start of continuous antihypertensive medication, non-adherent patients had 3.81 [95% confidence interval (CI) 2.85-5.10] and 3.01 (95% CI: 2.37-3.83) times higher odds of stroke death when compared with the adherent patients. The corresponding odds ratio (OR) for stroke hospitalization was 2.74 (95% CI: 2.35-3.20) at Year 2 and 1.71 (95% CI: 1.49-1.96) at Year 10. In the stroke-event year, the ORs were higher, 5.68 (95% CI: 5.05-6.39) for stroke death and 1.87 (95% CI: 1.72-2.03) for hospitalization. Among those using agents acting on the renin-angiotensin system combined with diuretics or β-blockers, these ORs were 7.49 (95% CI: 5.62-9.98) and 3.91 (95% CI: 3.23-4.75), respectively. The associations between non-adherence and stroke followed a dose-response pattern--the poorer the adherence, the greater the risk of death and hospitalization due to stroke.
Conclusion: These data suggest that poor adherence to antihypertensive therapy substantially increases near- and long-term risk of stroke among hypertensive patients.
Keywords: Adherence; Antihypertensive therapy; Hypertension; Mortality; Stroke.
Comment in
-
Long-term adherence to therapy: the clue to prevent hypertension consequences.Eur Heart J. 2013 Oct;34(38):2931-2. doi: 10.1093/eurheartj/eht299. Epub 2013 Aug 29. Eur Heart J. 2013. PMID: 23990601 No abstract available.
Similar articles
-
Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke.J Am Coll Cardiol. 2016 Apr 5;67(13):1507-1515. doi: 10.1016/j.jacc.2016.01.044. J Am Coll Cardiol. 2016. PMID: 27150680 Free PMC article.
-
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death.J Gen Intern Med. 2010 Jun;25(6):495-503. doi: 10.1007/s11606-009-1240-1. Epub 2010 Feb 18. J Gen Intern Med. 2010. PMID: 20165989 Free PMC article.
-
Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.Am J Med. 2015 Nov;128(11):1195-203. doi: 10.1016/j.amjmed.2015.04.034. Epub 2015 Jun 11. Am J Med. 2015. PMID: 26071821
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002003. doi: 10.1002/14651858.CD002003.pub3. PMID: 17253471 Updated. Review.
-
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2018 Nov 14;11:CD008170. doi: 10.1002/14651858.CD008170.pub3. PMID: 25577154 Updated. Review.
Cited by
-
Pharmacovigilance monitoring and treatment adherence in patients on antihypertensive drugs at a tertiary care centre.Drugs Context. 2024 Oct 22;13:2024-5-2. doi: 10.7573/dic.2024-5-2. eCollection 2024. Drugs Context. 2024. PMID: 39469027 Free PMC article.
-
Measuring the Influence of Side Effect Expectations, Beliefs, and Incident Side Effects on the Risk for Drug Discontinuation Among Individuals Starting New Medications, a Cross-sectional Study.Patient Prefer Adherence. 2024 May 17;18:979-989. doi: 10.2147/PPA.S451012. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38774475 Free PMC article.
-
Lifestyle or pharmacotherapy in cardio-metabolic disease prevention.Ther Adv Cardiovasc Dis. 2023 Jan-Dec;17:17539447231177175. doi: 10.1177/17539447231177175. Ther Adv Cardiovasc Dis. 2023. PMID: 37381922 Free PMC article. Review.
-
Medication Adherence Among Hypertensive Patients Attending Different Primary Health Centers in Abha, Saudi Arabia: A Cross-Sectional Study.Patient Prefer Adherence. 2022 Oct 19;16:2835-2844. doi: 10.2147/PPA.S388365. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36303595 Free PMC article.
-
Laboratory testing and antihypertensive medication adherence following initial treatment of incident, uncomplicated hypertension: A real-world data analysis.J Clin Hypertens (Greenwich). 2022 Oct;24(10):1316-1326. doi: 10.1111/jch.14567. Epub 2022 Sep 20. J Clin Hypertens (Greenwich). 2022. PMID: 36125169 Free PMC article.
References
-
- The GBDS consortium. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0. - DOI - PMC - PubMed
-
- The GBDS consortium. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. doi:10.1016/S0140-6736(12)61689-4. - DOI - PubMed
-
- Kinlay S. Changes in stroke epidemiology, prevention, and treatment. Circulation. 2011;124:e494–e496. doi:10.1161/CIRCULATIONAHA.111.069633. - DOI - PMC - PubMed
-
- Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314–323. doi:10.1161/CIRCULATIONAHA.111.018820. - DOI - PubMed
-
- The GBDS consortium. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260. doi:10.1016/S0140-6736(12)61766-8. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
